BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer.
Gary M MiddletonYiqun YangCatarina D CampbellThierry AndréChloe E AtreyaJan H M SchellensTakayuki YoshinoJohanna C BendellAntoine HollebecqueAutumn J McReeSalvatore SienaMichael S GordonJosep TaberneroRona YaegerPeter J O'DwyerFilip De VosEric Van CutsemJohn M MillhollandJan C BraseFatima RangwalaEduard GasalRyan B CorcoranPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
BM subtype is significantly associated with the outcome of combination dabrafenib, trametinib, and panitumumab therapy and may serve as a standalone predictive biomarker beyond mutational status. Our findings support a more nuanced approach to targeted therapeutic decisions that incorporates assessment of transcriptional context.